REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

Table 3

Characteristics of patients who responded to ICI-2.

No.	ICI-1 regimen	IMDC score at ICI-1	Best response at ICI-1	Therapies prior to ICI-1	Reason for ICI-1 discontinuation	ICI-2 regimen	IMDC score at ICI-2	Best response at ICI-2	Therapies between ICI regimens	Treatment-free interval (months)	Ongoing ICI-2 therapy
1	Nivolumab + ipilimumab	Favorable	CR	None	Progression	Nivolumab	Intermediate	CR	Pazopanib	No	Yes
2	Nivolumab + ipilimumab	Poor	PR	None	Toxicity (meningitis)	Nivolumab	Intermediate	PR	No	8.9	Yes
3	Nivolumab	Favorable	PR	Interferon, sunitinib, sorafenib, everolimus,	Clinical decision	Nivolumab	Intermediate	PR	No	12.0	Yes
4	Nivolumab	Intermediate	PR	Pazopanib	Clinical decision	Nivolumab	Intermediate	PR	No	5.0	No (progression)
5	Nivolumab	NA	SD	Sunitinib, pazopanib	Progression	Nivolumab	Favorable	PR	Cabozantinib	No	No (progression)
6	Nivolumab	Intermediate	PD	Everolimus, sunitinib	Progression	Nivolumab	Poor	PR	Sorafenib, nivolumab^2, cabozantinib	No	No (progression)
7	Nivolumab	Intermediate	PD	Sunitinib, pazopanib, everolimus, sorafenib, bevacizumab, INVAC-1^1	Progression	Nivolumab	Poor	PR	Sunitinib, cabozantinib	No	No (progression)

¹INVAC-1: DNA vaccine encoding human telomerase reverse transcriptase (hTERT). ²Patient underwent two rechallenges of nivolumab which were independently compared to the first ICI regimen. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; ICI, immune checkpoint inhibitor; NA, not available.